BAZ1B

Across TCGA pan-cancer cohorts, BAZ1B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BAZ1B data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BAZ1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BAZ1B expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LUAD, UCEC, and COAD are the cancer types where BAZ1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.068	0.788	<.001	32	view →
UCEC	DFS	Median	All	0.942	0.622	.010	26	view →
COAD	OS	Median	II,III,IV	0.301	0.613	.006	11	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	DFS	Median	All	1.000	0.340	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BAZ1B–LUAD (OS)

Open the LUAD breakdown →